- Investopedia•23 hours ago
Alexion has shelved its mucopolysaccharidosis drug SBC-103, which it acquired in 2015.
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
A tougher stance in the U.K. on funding expensive medicines for rare diseases is raising questions about the government’s pledges to support a life-sciences industry that’s already rattled by Brexit.
ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance
Alexion Pharmaceuticals, Inc. (ALXN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||130.90 x 100|
|Ask||130.98 x 100|
|Day's Range||129.60 - 132.78|
|52 Week Range||109.12 - 162.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||79.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|